ΔΗΜΟΣΙΕΥΣΕΙΣ
PUBLIC
Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology
Agorastos T, Chatzistamatiou K, Katsamagkas T, Koliopoulos G, Daponte A, Constantinidis T, Constantinidis TC; HERMES study group.
19 Αυγ 20
3:42 ΜΜ
Distinct demographic factors influence the acceptance of vaccination against HPV.
Agorastos T, Chatzistamatiou K, Zafrakas M, Siamanta V, Katsamagkas T, Constantinidis T, Lampropoulos A; Lysistrata Study Group.
28 Αυγ 20
1:37 ΜΜ
Epidemiology of HPV infection and current status of cervical cancer prevention in Greece: final results of the LYSISTRATA cross-sectional study
Agorastos T, Chatzistamatiou K, Zafrakas M, Siamanta V, Katsamagkas T, Constantinidis TC, Lampropoulos AF; LYSISTRATA study group.
19 Αυγ 20
3:44 ΜΜ
Response to: Media effect-letter to the editor about the manuscript titled Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine
Sotiriadis A, Dagklis T, Siamanta V, Chatzigeorgiou K, Agorastos T; LYSISTRATA Study Group.
19 Αυγ 20
3:45 ΜΜ
Letter to the editor referring to the manuscript entitled: "Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine" reported by Sotiriadis et al.
Chatzistamatiou K, Sotiriadis A, Agorastos T.
19 Αυγ 20
3:47 ΜΜ
Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine
Sotiriadis A, Dagklis T, Siamanta V, Chatzigeorgiou K, Agorastos T; LYSISTRATA Study Group.
19 Αυγ 20
3:50 ΜΜ
